Kornimate/medical-research-clean huggingface dataset:
postmenopausal progestins, mi and stroke

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Disease; Cerebrovascular Accident; Myocardial Infarction; Postmenopause

Summary: to evaluate the cardiovascular effects of postmenopausal hormone replacement therapy and the suspected beneficial effects on myocardial infarction and stroke.

background: post-menopausal women who use estrogens generally experience at once a reduced risk of coronary heart disease and, at the same time, an increased risk of endometrial cancer. in order to protect the endometrium from unopposed estrogens, many physicians now recommend the addition of a progestin during 10-13 days of the cycle. progestins may be implicated in the increased risk of myocardial infarction in women on oral contraceptives. design narrative: this was a case-control study. the computerized files of the group health cooperative (ghc) in seattle were used to identify cases. all postmenopausal women, aged 40 to 79, were eligible as cases if, according to world health organization criteria, they presented with a fatal or non-fatal myocardial infarction. a random sample of women listed in the enrollment files at ghc served as a source of potential controls. review of the out-patient medical records, performed by an assistant blind to case-control status ensured that all study subjects met the same criteria. telephone interviews were used to obtain information about exposure to postmenopausal hormones as well as known risk factors. the computerized pharmacy records at ghc provided additional information about exposure. frequency matching controlled for the potential confounding effects of age and year of presentation. stratification and logistic regression were used in data analysis. the study was renewed in 1995 to make more precise some of the indeterminate findings related to current use, cumulative dose and duration of use but also to extend the assessment of the risk or benefit to incident strokes. the study ended in january, 1999.

Eligibility criteria:
no eligibility criteria
eama sarcopenia in acute care patients in 9+european countries

Conditions: Sarcopenia; Malnutrition

Summary: this collaborative study in 9 geriatrics units across europe aims to apply emerging research to clinical practice, following the "action-research philosophy" (11). the overall goal is to improve care in patients with - and help prevent - sarcopenia. understanding the frequency of and risk factors for developing sarcopenia in an acute hospital setting, may help shed light on potential interventions and thus inform the development of future therapeutic strategies. it involves crucial implications for research, clinical practice, and policy towards optimal aging.

background: sarcopenia is a nutrition-related disease leading to physical impairment and adverse clinical outcomes. data regarding its characteristics in hospitalized patients are limited. aim: this study will assess in older patients admitted to acute medical wards, the prevalence, incidence, and risk factors for development of sarcopenia, or alteration in its severity, and evaluate associated clinical adverse outcomes. methods: this collaboratively-designed, longitudinal prospective observational study will be carried out in patients aged \>70 admitted to acute geriatric units in 9 european centers. the new sarcopenia diagnostic criteria of the european working group on sarcopenia 2 (ewgsop2) will be tested at admission and discharge, using isometric handgrip dynamometry, gait speed, and, pragmatically, calf circumference. there will be 3- and 12-month telephone follow-up (including the sarc-f questionnaire). discussion: our study will be the first collaboration to assess the prevalence and incidence of sarcopenia (ewgsop2) and its risk factors in hospitalized patients across europe.

Eligibility criteria:
inclusion criteria: * patients aged \>70 admitted to acute hospital medical units exclusion criteria: * length of hospital stay anticipated to be \<24 hours * hip/lower limb fractures * major amputations of the lower leg * terminally ill patients admitted for palliative care

Keywords: sarcopenia malnutrition ewgsop2 older people acute care hospitalized
development of a non-invasive dna methylation-based assay system for the risk assessment of urothelial carcinoma

Conditions: Bladder Cancer

Summary: bladder cancer ranks the ninth in worldwide cancer incidence. approximate 90% of bladder cancer is the malignancy of urothelium tissues, the urothelial cancer (uc). the mortality of bladder cancer is mainly due to recurrence and metastasis. unfortunately, the currently available cytology or cystoscopy examination is of limited value because of low sensitivity of early disease. new biomarkers as well as detection technology are thus required to improve early diagnosis. by the aid of quantitative methylation-specific pcr (qmsp), which allows detecting tumor-derived dna from tissues and body fluids, dna methylation-based assay is thus developing for early detection and prognosis. the goal of this proposed project is to develop a panel of dna-methylation based biomarkers for uc diagnosis, prognosis, and prediction of responses to therapy (especially the recurrence, invasion, survival, and responses to therapeutic agents). although numerous studies have investigated the aberrant promoter hypermethylation in bladder cancers or uc, inconsistent results are observed. dna hypermethylation determination may rely on not only the conditions of qmsp, but also the biopsy specimens of different race, environmental expose factors, and regional variation. we thus need to profile the dna methylation pattern of uc patients in taiwan to establish a panel of potential prediction biomarkers for local patients.

in the recent years, technologies of genomics, expression analysis and proteomics have been brought to guide the study of risk assessment and early detection of cancers. this proposed study aims to develop a non-invasive dna methylation-based assay system elucidating a panel of aberrantly hypermethylated genes from urothelial tumors and urine sediments, to improve the risk assessment of urothelial carcinoma; such as early diagnosis, prognosis, and prediction of response to therapeutic regimes. this proposal will establish several techniques to study the methylation status on gene promoter regions. three tasks will be achieved in this study: (1) profiling the aberrant dna methylation in urothelial carcinoma and determining potential prediction biomarkers. (2) establishing a non-invasive assay by detecting dna hypermethylation status in exfoliated cells collected from void urine; (3) mapping the dna hypermethylation changes from normal to malignant urothelial tumors and studying the underlying mechanism. through the collaboration of a genetic toxicologist (te-chang lee, phd, ibms), a urologist (yeong-shiau pu, md/phd, ntuh) and epidemiologists (hung-yi chiou, phd, taipei medical university), we will explore the risk biomarkers for urothelial carcinoma.

Eligibility criteria:
inclusion criteria: * those with histopathological-confirmed urothelial carcinoma will be included. exclusion criteria: * those were younger than 40 years old or with previous history of any other cancers will be excluded.
the prognosis of graft using plastic cannula in hemodialysis

Conditions: End Stage Renal Failure on Dialysis

Summary: the purpose of this study is to evaluate the complication of the puncture related complication in avg (arteriovenous graft) such as pseudoaneurysm and hematoma, and the dialysis adequacy using plastic cannula versus metal needle in hemodialysis patients

1. ultrasonography is performed to determine the maturity of vascular access 4 weeks after avg creation. 2. the first puncture is performed with plastic cannula or metal needle when it is judged that the blood vessel has matured. 3. four skilled nurses perform vascular access puncture with plastic or metal needle 4. ultrasound are used to evaluate and record the complications related to the puncture in plastic or metal needle group every month. 5. complications and dialysis adequacy between the two groups will be evaluated after 6 months

Eligibility criteria:
inclusion criteria: * patients receiving hemodialysis treatment using avg exclusion criteria: * age under 20 years old or over 75 years old * abnormal skin condition using immunosuppressants such as steroids. * skin disorder * metal allergy
multicenter registry of very early and late clinical outcomes to everolimus-eluting cobalt-chromium stent in patients with st elevation myocardial infarction

Conditions: ST-elevation Acute Myocardial Infarction; STEMI

Summary: to compare early and late clinical outcomes with everolimus-eluting cobalt-chromium stent in patients with st-elevation acute myocardial infarction, as well as identify the characteristics and efficacy of cocr-ees. also, oct sub-analysis will be conducted


Eligibility criteria:
inclusion criteria: 1. patients with stemi who are able to undergo cocr-ees implantation. 2. patients with no history of pci in the target vessel 3. patients who are 20 or older at the time of informed consent 4. patients who provided written informed consent by himself/herself 5. patients who are judged by their treating physician to be able to undergo pci with cocr-ees 6. patients for whom thrombus aspiration prior to cocr-ees implantation can be recommended 7. patients who meet all the following vascular inclusion criteria i.patients with target lesion in native coronary artery ii.patients with visual maximum vessel diameter of the target stent site in target lesion 8. patients were obtained finally revascularization of timi 3 by visual observation in the target vessel 9. patients who are able to treat with cocr-ees the diameter 2.5mm or more and 3.5mm or less and the length of 8mm or more and 28mm or less. exclusion criteria: 1. patients participating in the other ongoing registry or clinical study(except post-marketing surveillance of cocr-ees), or receiving treatment which may impact on endpoints of this study. 2. patients presenting with cardiogenic shock 3. patients for whom 12-month and 36-month cag and clinical follow up is considered difficult (patient's residence should also be taken into account) 4. patients with responsible lesion in left main trunk 5. patients with renal insufficiency or with chronic renal failure with serum creatinine level of 2.0mg/dl or higher at visit 6. patients on hemodialysis 7. patients with a known history of adverse drug reactions to aspirin, or clopidogrel or prasugrel (this may not apply if safety of ticlopidine is confirmed as an alternative drug.) 8. patients who are below the age of 20 9. women who were positive in pregnancy test or wish to become pregnant during study duration 10. patients who newly developed ami attributable to the prior stented site 11. patients with a known history of allergy to drug, polymer, metal, and other materials used in cocr-ees 12. patients diagnosed with hepatic insufficiency 13. patients with target lesion in saphenous vein graft 14. patients with active malignant tumor
distal erosions and nail psoriasis

Conditions: Psoriatic Arthritis

Summary: nearly 30% of patients with cutaneous psoriasis (pso) developed psoriatic arthritis (psa). among these patients 20 % will have severe destructive arthritis. the risk of developing psa is significantly higher in patients with nail involvement (or = 2.24; 95% ci \[1.26-3.98\]). the risk is particularly high for the peripheral form of psa and onycholysis (or=2.80; 95% ci \[1.34-5.85\]). thus the investigators wanted to test the hypothesis that onycholysis, in patients without psa, is a potential clinical marker of subclinical distal enthesopathy and, by extension, of bone micro-structural alterations. patients and methods the investigators will recruit 4 groups of subjects: 1. patients with peripheral psa, 2. patients with psoriatic nail onycholysis, 3. patients with pso only 4. healthy match control subjects. the investigators will assess the presence of enthesopathy by ultrasonography and bone structural damages (by hr-pqct) in all subjects at baseline and 4 years.


Eligibility criteria:
inclusion criteria: * adults over 18 years and until 65 years * both gender * covered by the french national insurance * subjects entering one of the 4 groups. exclusion criteria: * treatment by biological agents are an exclusion criteria for pso, onycholysis and control patients. * pregnant women

Keywords: erosions onycholysis hr-pqct psoriatic arthritis
dietary intake of alpha-linolenic acid in elderly

Conditions: Cardiovascular Diseases; Inflammation; Metabolism Disorder, Lipid

Summary: the purpose of this study is to evaluate the antiatherogenic and anti-inflammatory potential of an adequate intake of alpha-linolenic acid in elderly.

there is growing evidence that diets high in long chain n-3 polyunsaturated fatty acids (pufa) decrease the risk of fatal ischemic heart disease.both epidemiologic studies and clinical trials demonstrate substantial cardioprotective effects of alpha linolenic acid (ala) from vegetable oils.however, little is known about the relation of the dietary intake of ala with ischemic heart disease among older adults.in this study, elderly volunteers will be asked to ingest a supplement of a vegetable oil providing 1g of ala, or an equivalent amount of linoleic acid as sunflower oil, for a diet period of 6 weeks.serum samples will be collected before the dietary intervention and 6 weeks later.plasma biomarkers of inflammatory, lipid cardiovascular risk factors and serum and red cell membrane fatty acid composition will be determined on all samples.

Eligibility criteria:
inclusion criteria: * elderly patients over 65 years old exhibiting clinical indices of cardiovascular disease * male or female * subjects who were hospitalized in the geriatric unit of the emile roux hospital (ap-hp) * mmse (mini mental state examination)score \> or = 15 * supervision available for study medication * able to ingest oral diet exclusion criteria: * patients unable to understand the objectives of the dietary intervention * patients in paliative care * patients receiving supplement diets

Keywords: alphalinolenic acid lipid cardiovascular risk factors inflammation
migraine among sohag university students

Conditions: Migraine

Summary: diagnosis of migraine among students and detect frequency among them and detect how far migraine affect their life


Eligibility criteria:
inclusion criteria: * age from 18 to 25 years old. * students accept to give informed consent exclusion criteria: * students refused to give informed consent * age less than 18 or more than 25 ears old.
"bronchoscopic argon plasma coagulation for managing endobronchial carcinoid lesions

Conditions: Endobronchial Carcinoid

Summary: a small tube will go through the respiratory tract and a non contact cauterization will be done to the inside tumor

fiberoptic bronchoscopy will go through the tracheobronchial tree and after localization of the tumor, argon plasma coagulation by initiation non contact electrocautery will be done to the tumor

Eligibility criteria:
inclusion criteria: 1 - cooperative patient with written informed consent. 2- patients diagnosed with endobronchial carcinoid. 3- patients fit for fiberoptic bronchoscopy. 4- patients unwilling or unfit for surgery. exclusion criteria: 1 -poor karnofsky score. 2- patients unwilling or unfit for bronchoscopy. 3- extraluminal lesion. 4- patients with pacemaker. 5- forced expiratory volume 1 is less than one litre.

Keywords: argon plasma coagulation fiberoptic bronchoscopy endobronchial carcinoid
investigation into the ratio of ldl-cholesterol to hdl-cholesterol improvement after statin treatment in korean patients

Conditions: Dyslipidemias

Summary: an observational, non-interventional, multi-centre study to provide further information on the ratio of ldl-c to hdl-c improvement after statin treatment in korean patients group.


Eligibility criteria:
inclusion criteria: * subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia * subjects who have at least made 1 visit to the outpatient clinic within previous 6 months * subjects who have records of both ldl-c and hdl-c before \& after statin treatment (at least four weeks after statin taking) exclusion criteria: * subjects who are unwilling or unable to provide their examination and lab result of medical chart.

Keywords: ratio improvement ldl-c hdl-c ratio of low density lipoprotein cholesterol to high density lipoprotein cholesterol improvement high density lipoprotein cholesterol
cardiac toxicity in medical treatment of breast cancer

Conditions: Heart Failure; Breast Cancer

Summary: this study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. in a prospective study human epidermal growth factor receptor 2 (her2) positive breast cancer patients scheduled for trastuzumab treatment at odense university hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.


Eligibility criteria:
inclusion criteria: * diagnosis of her2 positive breast cancer * adjuvant treatment with trastuzumab exclusion criteria: * left ventricle ejection fraction (lvef) \<50% * chronic or persistent atrial fibrillation * history of moderate or severe valvular heart disease.

Keywords: heart failure related to medical treatment of breast cancer
a study in patients with mild or moderate ulcerative colitis who take a tnf inhibitor. the study investigates whether bowel inflammation improves when patients take bi 655130 in addition to their current therapy

Conditions: Colitis, Ulcerative

Summary: the objectives of this trial are safety and efficacy (proof-of-concept) of induction of mucosal healing by bi 655130 add-on therapy in patients with mild or moderate ulcerative colitis and persisting endoscopic activity despite pre-existing tnfi treatment. this trial will explore safety and efficacy of a dose of bi 655130 that was modelled to achieve the similar exposures as the highest exposures tested and found safe and tolerable in preceding single and multiple dose studies in healthy subjects, as add-on to pre-existing tnfi (tumor necrosis factor inhibitor) treatment. secondary and further objectives include assessment of the pharmacokinetic (pk) profile of bi 655130 and early exploration of specific biomarkers with potential usefulness to predict clinical efficacy or safety outcome or help understand bi 655130's mode of action.


Eligibility criteria:
inclusion criteria * 18 - 75 years at screening and randomisation * diagnosis of ulcerative colitis \>= 5 months prior to screening * receiving tnfi treatment with doses (i.e. dose and dosing interval) unchanged for \>= 4 months (infliximab) or \>= 2 monaten (adalimumab or golimumab) prior to randomisation * mild or moderate disease activity, defined as total mayo score (mcs) (\<= 10) * further inclusion criteria apply exclusion criteria: * prior use of more than two different tnf inhibitors or vedolizumab * extensive colonic resection * evidence of infection with c. difficile or other intestinal pathogen \<28 days prior to screening * active or latent tuberculosis * further exclusion criteria apply
therasphere for unresectable primary or secondary liver neoplasia

Conditions: Liver Cancer; Liver Neoplasms; HepatoCellular Carcinoma

Summary: this is not a research study. the purpose is to provide supervised access to therasphere® therapy at this institution.


Eligibility criteria:
inclusion criteria: * patients will be recruited from the patient population referred to the principal clinician for regional liver cancer therapy. * potential candidates are those diagnosed with primary or secondary liver neoplasia. the histopathology confirmation criterion may be waived in patients with a radiographically identifiable liver mass, known laboratory or clinical risk factors for cancer or elevated tumor markers and clinical findings. guidelines from the american association for the study of liver diseases (aasld) and the european association for the study of the liver (easl) describe in detail the approach and algorithm for diagnosing hepatocellular carcinoma (hcc). * eastern cooperative oncology group (ecog) performance status score 0 - 2 * life expectancy ≥ 3 months * \> 4 weeks since prior radiation, surgery or chemotherapy * able to comprehend and provide consent in accordance with institutional and federal guidelines exclusion criteria: * any other liver therapy planned for cancer treatment * uncorrectable flow to the gastrointestinal tract * estimated radiation doses to the lungs greater than 30 gy in a single administration or 50 gy in multiple administrations * significant extrahepatic disease representing imminent life-threatening outcome * pregnancy

Keywords: humanitarian device exemption liver disease hde #980006
clinical evaluation of a daily wear monthly replacement silicone hydrogel lens

Conditions: Refractive Errors

Summary: the purpose of this clinical study is to evaluate the safety and effectiveness of an investigational soft contact lens compared to a commercially available soft contact lens when worn for daily wear and replaced monthly.

subjects are expected to attend 6 study visits. the expected duration of study lens exposure is approximately 3 months.

Eligibility criteria:
key inclusion criteria: * successful wear of spherical daily wear frequent replacement soft contact lenses for distance correction in both eyes during the past 3 months for a minimum of 5 days per week and 8 hours per day. * manifest cylinder equal to or less than 0.75 diopter (d) in each eye. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment. * habitually wearing biofinity contact lenses. * monovision contact lens wearers. * other protocol-specified exclusion criteria may apply.

Keywords: contact lens daily wear vision correction